IL-7 variants with reduced immunogenicity
AssigneeMerck Patent GmbH
InventorsStephen Gillies, Jeffrey Way
Life of this patent
Estimating the term…
Abstract
Modified interleukin-7 (IL-7) polypeptides are disclosed. The modified IL-7 polypeptides have alterations to one or more potential T-cell epitopes, thereby to reduce a T-cell response.
Claims21
A polypeptide at least 80% identical to a human IL-7 moiety or an active portion thereof, the polypeptide comprising an amino acid substitution at one or more residues corresponding to Gln22, Leu24, Ile30, Phe39, Met54, Phe57, Arg58, Ala60, Leu63, Lys68, Met69, Leu77, Ile88, Val96, Leu104, Leu128, Met147, Thr149, or Lys150.
A polypeptide comprising a human IL-7 moiety having a T-cell epitope modified to reduce an anti-IL-7 T-cell response.
Dependencies are inferred from the claim text.